PPiSeq: High-Throughput Protein-Protein Interaction Sequencing
PPiSeq:高通量蛋白质-蛋白质相互作用测序
基本信息
- 批准号:10449402
- 负责人:
- 金额:$ 41.89万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2015
- 资助国家:美国
- 起止时间:2015-09-16 至 2025-06-30
- 项目状态:未结题
- 来源:
- 关键词:AnimalsAntiviral AgentsBar CodesBiological AssayCell Culture TechniquesCell physiologyCellsCommunitiesComplementCowpoxDHFR geneDataData SetDihydrofolate ReductaseDrug ScreeningDrug TargetingEpidemicFundingGrantHealthHepatitis EHerpesviridaeHumanInfectionInfluenza B VirusInfluenza C VirusLearningLibrariesMapsMeasuresMolecularMutagenesisNatural regenerationOpen Reading FramesOutputPathway interactionsPharmaceutical PreparationsProcessProtein FragmentProtein-Protein Interaction MapProteinsRabiesReadinessResearchResourcesScanningSystemTechnologyTestingVariantViralViral ProteinsVirulenceVirusWorkYeastsZoonosesbasedimerdrug testinggene synthesisgenetic analysisgenetic variantgenome-widehigh throughput screeninghuman coronavirushuman population geneticsparticlepathogenic virusprotein protein interactionscreeningsequencing platformsmall moleculesmall molecule librarieszoonotic spillover
项目摘要
Project Summary/Abstract
Emerging and endemic viral pathogens are a persistent threat to human health, the global economy, and national readiness. Viral proteins interact with host proteins to hijack host cells and replicate transmissible viral particles. Human-viral and viral-viral protein-protein interactions (PPls) have been comprehensively characterized for a limited set of viruses, identifying a "PPI profile" for each virus screened. However, these efforts have characterized only a small fraction of the known viruses. A complete viral-human PPI map would be an invaluable resource, enabling analyses of how often interacting viral proteins converge on common human protein targets, cellular functions, or pathways, and which of these interactions are associated with transmissibility or virulence. Combining the viral-human PPI map with human population genetic analyses will enable characterization of the molecular mechanisms underlying extant and ancient epidemics and how these PPIs drive much of human adaptation. In addition, PPI profiles of human viruses could be used to aid screening of animal reservoirs to identify potential threats before a zoonotic spillover occurs. Despite its great promise, characterization of the viral-human PPI map remains a challenge given the throughput of current viral-human PPI screening assays. Current high-throughput assays also lack a quantitative output, meaning that the emergent human-viral PPI map, or viral-viral PPI maps, would be difficult to exploit for important downstream variant scanning or drug screening applications. Here we will use a quantitative sequencing-based protein-protein interaction assay platform to screen for PPls between -24 million viral-human or viral-viral protein pairs. We will further develop this technology into a massively parallel drug screening platform and use it to screen >3 million drug-PPI combinations for small-molecule compounds that promote or antagonize a PPI. The viral-human PPI and drug-PPI maps developed here will be an invaluable resource for a broad research community. In addition, this work will establish new massively parallel and quantitative PPI and drug-PPI screening technologies that will scale with advances in gene synthesis, mutagenesis and sequencing, enabling parallel screening of tens of thousands of gene and gene variants of extant, emerging, and potentially zoonotic viruses.
项目概要/摘要
新出现的地方性病毒病原体对人类健康、全球经济和国家准备状况构成持续威胁。病毒蛋白与宿主蛋白相互作用,劫持宿主细胞并复制可传播的病毒颗粒。人类-病毒和病毒-病毒蛋白-蛋白相互作用 (PPls) 已针对一组有限的病毒进行了全面表征,为每种筛选的病毒确定了“PPI 图谱”。然而,这些努力仅描述了一小部分已知病毒的特征。完整的病毒-人类 PPI 图谱将是一种宝贵的资源,可以分析相互作用的病毒蛋白在常见的人类蛋白靶点、细胞功能或途径上聚合的频率,以及这些相互作用中哪些与传播性或毒力相关。将病毒-人类 PPI 图谱与人群遗传分析相结合,将能够表征现存和古代流行病的分子机制,以及这些 PPI 如何推动人类适应。此外,人类病毒的 PPI 谱可用于帮助筛查动物宿主,以便在人畜共患病蔓延发生之前识别潜在威胁。尽管前景广阔,但考虑到当前病毒-人 PPI 筛选测定的通量,病毒-人 PPI 图谱的表征仍然是一个挑战。目前的高通量检测还缺乏定量输出,这意味着新兴的人类-病毒 PPI 图谱或病毒-病毒 PPI 图谱将难以用于重要的下游变异扫描或药物筛选应用。在这里,我们将使用基于定量测序的蛋白质-蛋白质相互作用测定平台来筛选-2400万个病毒-人类或病毒-病毒蛋白质对之间的PPls。我们将进一步将该技术开发成大规模并行药物筛选平台,并用它来筛选超过300万种药物-PPI组合,以寻找促进或拮抗PPI的小分子化合物。这里开发的病毒-人类 PPI 和药物-PPI 图谱将成为广泛研究界的宝贵资源。此外,这项工作将建立新的大规模并行定量 PPI 和药物 PPI 筛选技术,这些技术将随着基因合成、诱变和测序的进步而扩展,从而能够并行筛选现有、新兴和潜在人畜共患病毒的数万个基因和基因变体。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
SASHA F LEVY其他文献
SASHA F LEVY的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('SASHA F LEVY', 18)}}的其他基金
High-throughput genetic interaction sequencing in mammalian cells
哺乳动物细胞中的高通量遗传相互作用测序
- 批准号:
9360136 - 财政年份:2016
- 资助金额:
$ 41.89万 - 项目类别:
PPiSeq: High-Throughput Protein-Protein Interaction Sequencing
PPiSeq:高通量蛋白质-蛋白质相互作用测序
- 批准号:
9145264 - 财政年份:2015
- 资助金额:
$ 41.89万 - 项目类别:
PPiSeq: High-Throughput Protein-Protein Interaction Sequencing
PPiSeq:高通量蛋白质-蛋白质相互作用测序
- 批准号:
10294207 - 财政年份:2015
- 资助金额:
$ 41.89万 - 项目类别:
PPiSeq: High-Throughput Protein-Protein Interaction Sequencing
PPiSeq:高通量蛋白质-蛋白质相互作用测序
- 批准号:
9288060 - 财政年份:2015
- 资助金额:
$ 41.89万 - 项目类别:
PPiSeq: High-Throughput Protein-Protein Interaction Sequencing
PPiSeq:高通量蛋白质-蛋白质相互作用测序
- 批准号:
9307578 - 财政年份:2015
- 资助金额:
$ 41.89万 - 项目类别:
Identification of phenotypic capacitors of environmental and genotypic variation
环境和基因型变异的表型电容器的鉴定
- 批准号:
7220829 - 财政年份:2007
- 资助金额:
$ 41.89万 - 项目类别:
Identification of phenotypic capacitors of environmental and genotypic variation
环境和基因型变异的表型电容器的鉴定
- 批准号:
7347536 - 财政年份:2007
- 资助金额:
$ 41.89万 - 项目类别:
相似海外基金
Development of a new generation of antiviral agents that are effective against drug-resistant viruses and prevent serious illness and sequelae.
开发新一代抗病毒药物,可有效对抗耐药病毒并预防严重疾病和后遗症。
- 批准号:
23K18186 - 财政年份:2023
- 资助金额:
$ 41.89万 - 项目类别:
Grant-in-Aid for Challenging Research (Exploratory)
A versatile structure-based therapeutic platform for development of VHH-based antitoxin and antiviral agents
一个多功能的基于结构的治疗平台,用于开发基于 VHH 的抗毒素和抗病毒药物
- 批准号:
10560883 - 财政年份:2023
- 资助金额:
$ 41.89万 - 项目类别:
Genetically encoded bicyclic peptide libraries for the discoveryof novel antiviral agents
用于发现新型抗病毒药物的基因编码双环肽库
- 批准号:
10730692 - 财政年份:2021
- 资助金额:
$ 41.89万 - 项目类别:
Design and synthesis of nucleosides to develop antiviral agents and oligonucleotide therapeutics
设计和合成核苷以开发抗病毒药物和寡核苷酸疗法
- 批准号:
21K06459 - 财政年份:2021
- 资助金额:
$ 41.89万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Genetically encoded bicyclic peptide libraries for the discoveryof novel antiviral agents
用于发现新型抗病毒药物的基因编码双环肽库
- 批准号:
10189880 - 财政年份:2021
- 资助金额:
$ 41.89万 - 项目类别:
Computer-aided identification and synthesis of novel broad-spectrum antiviral agents
新型广谱抗病毒药物的计算机辅助鉴定和合成
- 批准号:
2404261 - 财政年份:2020
- 资助金额:
$ 41.89万 - 项目类别:
Studentship
Develop broad-spectrum antiviral agents against COVID-19 based on innate immune response to SARS-CoV-2 infection
基于对 SARS-CoV-2 感染的先天免疫反应,开发针对 COVID-19 的广谱抗病毒药物
- 批准号:
10222540 - 财政年份:2020
- 资助金额:
$ 41.89万 - 项目类别:
Develop broad-spectrum antiviral agents against COVID-19 based on innate immune response to SARS-CoV-2 infection
基于对 SARS-CoV-2 感染的先天免疫反应,开发针对 COVID-19 的广谱抗病毒药物
- 批准号:
10669717 - 财政年份:2020
- 资助金额:
$ 41.89万 - 项目类别:
Association between sedentary lifestyle and liver cancer development in hepatitis C patients treated with direct-acting antiviral agents
接受直接抗病毒药物治疗的丙型肝炎患者久坐的生活方式与肝癌发展之间的关系
- 批准号:
20K10713 - 财政年份:2020
- 资助金额:
$ 41.89万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Develop broad-spectrum antiviral agents against COVID-19 based on innate immune response to SARS-CoV-2 infection
基于对 SARS-CoV-2 感染的先天免疫反应,开发针对 COVID-19 的广谱抗病毒药物
- 批准号:
10174522 - 财政年份:2020
- 资助金额:
$ 41.89万 - 项目类别:














{{item.name}}会员




